Physician

Barton C Brezina, MD

According to 2025 Medicare claims, Barton Brezina, MD (NPI: 1205824877) practices nephrology in the Augusta-Richmond County, GA-SC market, with the plurality of this provider's patient population coming from Richmond, GA. This provider's primary affiliated billing organization is NEPHROLOGY ASSOCIATES, PC (NPI: 1891744322; TIN: 581651447) and primary practice location at 30901-2642.

Brezina's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 957 traditional Medicare patients, billed 12,428 HCPCS/CPT codes, and received $390,436 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,808 prescription claims across 699 beneficiaries totaling $516,631 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 102 claims. Open Payments data shows 67 records totaling $16,111. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $704,802 and ending at $516,631. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,031	59,937	$534,439
2016	1,113	63,877	$544,138
2017	1,148	11,670	$517,952
2018	1,159	12,388	$502,541
2019	1,055	11,972	$481,224
2020	996	9,239	$457,141
2021	1,029	12,278	$472,265
2022	1,021	13,482	$434,149
2023	1,033	14,630	$425,661
2024	957	12,428	$390,436

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	564	3,878	$704,802
2016	593	4,198	$757,146
2017	664	4,163	$851,259
2018	670	4,183	$624,128
2019	647	3,721	$486,029
2020	622	3,700	$1,698,248
2021	617	3,678	$490,826
2022	598	2,652	$467,254
2023	606	2,476	$458,890
2024	699	2,808	$516,631

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	60	$7,745
2016	N/R	77	$11,490
2017	N/R	83	$8,510
2018	N/R	73	$9,153
2019	N/R	55	$7,574
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	62	$1,976
2023	N/R	N/R	N/R
2024	N/R	102	$1,617

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	594	1,097	$84
36415	Insertion of needle into vein for collection of blood sample	599	1,165	$9
80069	Kidney function blood test panel	574	1,073	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	596	1,056	$8
82043	Urine microalbumin (protein) level	585	1,011	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	124	7,274	$126,186
Veltassa	Patiromer Calcium Sorbitex	33	1,982	$66,587
Ozempic	Semaglutide	53	2,442	$53,296
Jardiance	Empagliflozin	48	2,649	$50,845
Kerendia	Finerenone	37	1,770	$37,684

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	25	$450
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	26	$447
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	25	$414
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	15	$298
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	11	$8

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	65	$2,156	Eli Lilly and Company
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$13,955	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Barton C. Brezina, MD?

Tedicare shows public-source Medicare data for Barton C. Brezina, MD (NPI 1205824877), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Barton C. Brezina, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Barton C. Brezina, MD?

Barton C. Brezina, MD is linked to NEPHROLOGY ASSOCIATES, PC (billing NPI 1891744322) in the available physician profile data.

Does Barton C. Brezina, MD have Open Payments data?

Barton C. Brezina, MD has 67 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.